What is it about?
Using mice, a chronic asthma model was set up. These mice were then split into control and treatment groups, where the treatment was either a secreted protein from A. viteae ES-62 or a small molecule analogue based on ES-62 (11a or 12b). Data showed that all treatment ameliorated symptoms of chronic asthma, namely cellular infiltration, airway thickening and mucus hyper-production.
Featured Image
Why is it important?
The data showing that small molecule analogues can also show efficacy makes them potential novel drug candidates, something that ES-62 could not be.
Read the Original
This page is a summary of: The parasitic worm-derived immunomodulator, ES-62 and its drug-like small molecule analogues exhibit therapeutic potential in a model of chronic asthma, Scientific Reports, January 2016, Springer Science + Business Media,
DOI: 10.1038/srep19224.
You can read the full text:
Contributors
The following have contributed to this page
